...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Cash

Great job RVXoldtimer. Thanks.

It all looks positive. Science is moving forward.

From a business and liquidity side I guess anything could happen like a buyout, a listing (doubtful with current private funding, arrangements and low valuation), etc.

From a shareholder perspective it looks like a very long journey ahead of us.

Also, looks like the AGM will just be another rubber stamp session with a bit of an update and Don floats off into the sunset for another well compensated year.

Of course, if there is good science presented on mCRPC it could change things but phase 3 will take a few years I'm sure.

Oh well, GLTA

Toinv

Share
New Message
Please login to post a reply